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There is considerable interindividual variation in
bioavailability of Methoxsalen (8-methoxypsoralen)
after ingestion of the standard dose used in photo-
chemotherapy (psoralen plus ultraviolet A). A dose
change may be used to alter the degree of photo-
sensitivity, although there is limited information on
the effect of 8-methoxypsoralen dose alterations on
phototoxicity within individuals. We studied the
effect of changes of 8-methoxypsoralen dose over a
narrow range in 15 subjects with psoriasis. Two
hours after ingestion, serum 8-methoxypsoralen con-
centration was determined and phototesting was
performed at 350 6 30 nm (0.45±14 J per cm2). The
minimal phototoxic dose at 72 h was recorded,
erythema was measured using a re¯ectance instru-
ment, and dose±response curves were constructed.
Each subject was tested on three occasions using
doses of 25 mg per m2 (conventional dose) or con-
ventional dose 6 10 mg. Median serum 8-methoxy-
psoralen concentration increased from 96 to 143 to
229 ng per ml with dose increases from conventional
dose ± 10 mg to conventional dose and conventional
dose + 10 mg, respectively (p < 0.001). The median
minimal phototoxic dose and D0.025 (the objective
equivalent of the minimal phototoxic dose derived
from the dose±response curve) were signi®cantly
reduced with increasing 8-methoxypsoralen dose
from conventional dose minus 10 mg (minimal
phototoxic dose 1.7 J per cm2; D0.025 2.8 J per cm
2)
to conventional dose (1.2; 1.4 J per cm2) and con-
ventional dose plus 10 mg (0.9; 1.0 J per cm2) (p
< 0.001). Change in 8-methoxypsoralen dose had no
detectable effect on the maximum slope of the psor-
alen plus ultraviolet A erythema dose±response
curve. Thus, 8-methoxypsoralen dose changes within
individuals, over a narrow but clinically relevant
range, signi®cantly altered the threshold response to
psoralen plus ultraviolet A erythema but not the rate
of increase in erythema with increasing ultraviolet A
dose. Key words: intraindividual/8-methoxypsoralen/
phototoxicity/photochemotherapy. J Invest Dermatol
116:813±815, 2001
C
ontrolled phototoxicity is used in the treatment of
chronic in¯ammatory dermatoses such as psoriasis.
Cutaneous sensitization to ultraviolet A (UVA) can
be achieved by systemic ingestion of psoralens in
psoralen plus UVA (PUVA) photochemotherapy
(Fitzpatrick et al, 1955). In Europe, microcrystalline 8-methoxy-
psoralen (8-MOP; Methoxsalen) is given at a standard dose of
0.6 mg per kg body weight or, more accurately, 25 mg per m2
body surface area (Sakuntabhai et al, 1995). There are no clinical
studies, however, to support this 8-MOP dosage regime as being
optimal for therapeutic ef®cacy or for minimizing side-effects such
as erythema. There is considerable variation in interindividual and,
to a lesser extent, intraindividual bioavailability of 8-MOP after a
standard oral dose and serum concentration is a poor indicator of
tissue levels (Lauharanta et al, 1982; SchaÈfer-Korting and Korting,
1982; Herfst and de Wolff, 1983; Marrakchi et al, 1991; Donath et
al, 1999). It appears that tissue 8-MOP concentration is a better
indicator of PUVA erythemal sensitivity than plasma levels (Yeo et
al, 2000). In addition, there is an inverse relationship between
serum 8-MOP concentration and UVA dose required to cause
minimal erythema (minimal phototoxic dose, MPD) (Ljunggren
et al, 1981; Goldstein et al, 1982; Honigsmann et al, 1982). No
information exists, however, concerning the effect of 8-MOP dose
changes over a narrow, clinically relevant range on the nature of the
UVA erythemal response in psoralen-sensitized skin within
individuals and this was the purpose of the study.
MATERIALS AND METHODS
Subjects Fifteen adults with chronic plaque psoriasis, about to start
systemic 8-MOP PUVA (10 female; median age 44 y; range 24±77 y;
skin types I (n = 1), II (n = 7), and III (n = 7)), were studied with
ethical approval. None of the subjects had a history of photosensitivity,
and none was receiving medication or UV therapy prior to the study.
Erythemal responses to PUVA were measured on the untanned normal
skin of the mid-back, avoiding the midline, in each subject.
Photoirradiation equipment An irradiation monochromator (Diffey
et al, 1984a), optically coupled to a liquid-®lled light guide, was used to
achieve a uniform irradiation ®eld of 1 cm diameter.
Serum 8-MOP concentration Two hours after ingestion of 8-MOP
(Methoxsalen, microcrystalline preparation, Crawford Pharmaceuticals,
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Milton Keynes, U.K.), a 20 ml blood sample was taken and serum was
prepared by centrifugation at 3000 rpm for 15 min at 4°C. Samples were
kept at ±20°C until assayed and then extracted into hexane following the
addition of 5-methoxypsoralen as internal standard. The hexane extract
was evaporated to dryness under nitrogen, and the residue was dissolved
in a mobile phase (40% acetonitrile, 60% deionized water) and
chromatographed on a reverse phase high performance liquid chromato-
graphy system using a UV/vis detector at 247 nm (P. Barn®eld,
Department of Chemical Pathology, St. Thomas's Hospital, London,
U.K.).
8-MOP dose range Each patient was tested on three occasions using
8-MOP doses of 25 mg per m2 (equivalent to 0.6 mg per kg), calculated
to the nearest 10 mg (Sakuntabhai et al, 1995) (conventional dose, CD),
or CD 6 10 mg. The order of dose allocation was randomly ascribed for
each patient.
PUVA phototesting Two hours after ingestion of 8-MOP, 11
adjacent sites on the mid-back were exposed to a geometric series of
doses at 350 6 30 nm (dose range 0.45±14 J per cm2, increment factor
1.4). Under these conditions, the spectral power distribution of the
irradiation monochromator approximates that of a typical PUVA type
UVA ¯uorescent lamp (e.g., Philips TL-09) (Sakuntabhai et al, 1993a).
The high irradiance of the monochromator (approximately 110 mW per
cm2) allowed considerably shorter exposure times than would have been
required had a conventional PUVA lamp been used.
Erythemal response The dose of UVA radiation required to cause
faint but easily discernible erythema in psoralen-sensitized skin was
de®ned as the MPD and was measured at 72 h. Following each of the
three 8-MOP doses, the visual MPD was determined and erythema
measurements were made in triplicate at each irradiated site and at
adjacent control sites, using a re¯ectance instrument (Diffey et al, 1984b).
In each subject, at each of the three 8-MOP doses, the increase (DE) in
mean erythema index compared with nonirradiated skin was plotted
against the logarithm of the UVA dose and a logit function was ®tted to
the data to construct dose±response curves (Diffey and Farr, 1991). The
dose of radiation required to cause an increase in erythema index of
0.025 (D0.025), clinically equivalent to the MPD, and the maximum
slope were calculated for each dose±response curve (Fig 1).
Statistical analysis Values given are median (range). The serum
8-MOP concentration, MPD, and D0.025 values for each of the three
doses were compared using within-subjects analysis of variance with log-
transformed data. Follow-up comparisons were made using Tukey's
procedure for multiple comparisons. Within-subjects analysis of variance
was used to compare the slopes of the dose±response curves at the three
8-MOP doses. A value of p < 0.05 was taken to be of statistical
signi®cance. A linear regression model, with no assumption of
independence for within-subjects repeated measures and with robust
variance estimates, was used to assess how much of the variation in log-
transformed MPD and D0.025 could be explained by variation in the
8-MOP serum level. Stata statistical software (Intercooled Stata for
Windows, release 6; Stata, Texas, 1999) was used.
RESULTS
Serum 8-MOP concentrations Two hours after ingestion of
8-MOP, serum concentrations of 8-MOP were measured in each
of the 15 subjects on three separate occasions after different oral
doses (Fig 2). 8-MOP concentration increased from a median
(range) value of 96 (45±199) to 143 (65±359) to 229 (133±347) ng
per ml with dose increases from CD ± 10 mg to CD and
CD + 10 mg, respectively (p < 0.001). The wide interindividual
variation in bioavailability of 8-MOP after each of these standard
oral doses is shown (Fig 2).
Serum 8-MOP concentrations and MPD and D0.025 With
increasing serum 8-MOP concentration, the MPD and D0.025
values fell signi®cantly (p = 0.002, p < 0.001, respectively). Only
30% of the variation in MPD and D0.025 could be explained by
variation in serum 8-MOP concentration, however.
MPD There was a signi®cant reduction in median (range) MPD
with increasing oral 8-MOP dose from CD ± 10 mg (1.7; 0.9±5.0)
to CD (1.2; 0.8±1.7) and CD + 10 mg (0.9; 0.5±1.7 J per cm2) (p
< 0.001) (Fig 3a). These data also demonstrate the variation in
MPD values at each of the 8-MOP doses.
PUVA erythema dose±response curves A signi®cant
reduction in median (range) D0.025 value occurred when the oral
8-MOP dose was increased from CD ± 10 mg (2.8; 0.8±8.2) to
CD (1.4; 0.7±2.6) and CD + 10 mg (1.0; 0.4±2.5 J per cm2)
(p < 0.001) (Fig 3b). The wide variation in individual D0.025 values
at each of the oral 8-MOP doses is also shown (Fig 3b). There was
no detectable effect of the 8-MOP dose on the maximum slope of
the PUVA erythema dose±response curves [CD ± 10 mg (median
217; range 77±617) to CD (249; 180±372) and CD + 10 mg (256;
184±393) (n = 15; p = 0.07)].
Figure 1. A typical PUVA erythema dose±response curve in one
subject. Each point represents the increase in erythema index compared
with unirradiated sites (DE; mean 6 SD). The line drawn through the
data points is the logit function obtained by regression analysis. The
D0.025 (as indicated) is the dose of UVA radiation required to cause an
increase in erythema index of 0.025.
Figure 2. Serum 8-MOP concentration increased with increasing
oral 8-MOP doses. There was a signi®cant difference in concentrations
across the three doses (p < 0.001). The differences in concentrations for
the doses CD ± 10 mg and CD (p = 0.004), and CD ± 10 mg and
CD + 10 mg (p < 0.001) were also highly unlikely to be chance
®ndings. The difference in 8-MOP concentrations between CD and
CD + 10 mg was less clearly signi®cant, however (p = 0.15).
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DISCUSSION
We have assessed the effects of small, clinically relevant 8-MOP dose
changes on the characteristics of PUVA erythema 72 h after UVA
exposure. The ®ndings relate to the use of microcrystalline 8-MOP
preparations. There was a signi®cant reduction in the dose of UVA
required to cause threshold erythema in psoralen-sensitized skin
when the dose of 8-MOP was increased by 10 mg increments. This
was supported by the ®ndings of signi®cant reductions in D0.025
values, which are the dose±response curve equivalent values of the
MPD.
There is limited information that, over a wide 8-MOP
concentration range, there is an inverse correlation with the
MPD, and the ratio of 8-MOP concentration to MPD is constant
at higher 8-MOP doses (Ljunggren et al, 1981). In that study the
effect of large variations in oral 8-MOP dose on the MPD was
examined within individuals, however, and at the lowest 8-MOP
dose the ratio of serum concentration and MPD was not constant,
which may re¯ect the strong ®rst pass metabolism of 8-MOP
(Brickl et al, 1981). Additionally, a signi®cant association exists
between erythemal sensitivity, 8-MOP dose, skin type, and past
history of PUVA treatment (Sakuntabhai et al, 1994).
The ®ndings of this study suggest that the common practice of
giving a 10 mg greater dose of 8-MOP to those in whom a
phototoxic response is undetectable, on phototesting after the CD,
is appropriate as the MPD and D0.025 would be expected to reduce
by 25% and 29%, respectively.
The susceptibility to burning in the clinical setting is related to the
steepness of an individual patient's PUVA dose±response curve
(Sakuntabhai et al, 1993b). Our ®ndings did not show a signi®cant
effect of these relatively small dose changes on the maximum slope of
the UVA erythema dose±response curve, however. The study was
small and we may not have detected a psoralen dose effect on the rate
of increase in erythema response to increasing UVA doses, for this
reason. The absence of a detectable, large effect on the slope of
response, however, calls into question the value of a small (10 mg)
reduction in 8-MOP dose for patients experiencing painful
erythema (``burning'') episodes during treatment. A larger dose
reduction may be of bene®t, or a greater reduction in UVA dose may
be more appropriate.
In conclusion, we have found that small variations in 8-MOP dose
lead to changes in the threshold erythema response (MPD; D0.025)
that are likely to be clinically important but do not have detectable
effects on the maximum slope of the PUVA erythema dose±response
curve.
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Figure 3. The MPD and D0.025 values reduced
with increasing oral 8-MOP doses. (a) MPD and
(b) D0.025. There was a signi®cant difference in
MPD and D0.025 across the three doses (p
< 0.001) and between CD ± 10 mg and CD (p
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respectively). The difference between CD and
CD + 10 mg for MPD and D0.025 was less clearly
signi®cant (p = 0.03; p = 0.07, respectively).
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